Simple Summary Bladder cancer is the ninth most common cancer worldwide. Immune
checkpoint inhibitors, a novel class of immunotherapy drugs that restore natural antitumoral …

Bladder cancer is the 10 th most commonly occurring malignancy worldwide with a 75% of 5-
year survival rate, while it ranks 13 th among the deaths occurring due to cancer. The …

Purpose Vinflunine (VFL) is a new microtubule inhibitor that has activity against transitional
cell carcinoma of urothelial tract (TCCU). We conducted a randomized phase III study of VFL …

The aryl hydrocarbon receptor (AhR) is a ligand-activated transcriptional factor that
dimerizes with aryl hydrocarbon receptor nuclear translocator (ARNT). This complex binds to …

Introduction: Randomized controlled trials of platinum-based neoadjuvant chemotherapy
(NAC) for bladder cancer have shown that patients who achieve a pathologic response to …

Abstract Objective Low dose (10–25 mg/week) methotrexate is widely used for the
management of systemic inflammatory diseases, and is considered to be relatively safe …

Our recent study of the micro RNA (mi RNA) expression signature of bladder cancer (BC) by
deep‐sequencing revealed that two mi RNA, micro RNA‐139‐5p/micro RNA‐139‐3p were …

CONTEXT: We present a summary of the Second International Consultation on Bladder
Cancer recommendations on chemotherapy for the treatment of bladder cancer using an …

The identification of patients with high-risk bladder cancer is important for the timely and
appropriate treatment of this lethal disease. The understanding of the natural history of …

OBJECTIVES: Examine the association between clinical, demographic, and socioeconomic
factors and the receipt of systemic chemotherapy for bladder cancer. Examine factors …